Congenital CMV Infection
About one out of every 200 infants is born with congenital cytomegalovirus (CMV) infection. However, only about one in five babies born with congenital CMV infection will have long-term health problems.
A pregnant woman can pass CMV to her fetus following primary infection, reinfection with a different CMV strain, or reactivation of a previous infection during pregnancy. Risk of transmission for primary infection is 30 to 40% in the first and second trimesters, and 40 to 70% in the third trimester. The risk of transmission following non-primary infection is much lower (3%). The risk of complications to the fetus is greatest if a primary infection occurs during the first trimester.
Most infants with congenital CMV infection never have health problems. About 10% of infants with congenital CMV infection will have health problems that are apparent at birth, which include:
- Jaundice (yellowing of the skin or whites of the eyes)
- Microcephaly (small head)
- Intrauterine growth restriction (low weight)
- Hepatosplenomegaly (enlarged liver and spleen)
- Retinitis (damaged eye retina)
About 40 to 60% of infants born with signs of congenital CMV disease at birth will have long-term health problems, such as:
- Hearing loss
- Vision loss
- Intellectual disability
- Microcephaly (small head)
- Lack of coordination or weakness
Some infants without signs of congenital CMV disease at birth may later have hearing loss, but do not appear to have other long-term health problems. Hearing loss may be present at birth or may develop later, even in infants who passed their newborn hearing test. About 10 to 20% of infants with congenital CMV infection who have no signs at birth will have, or later develop, hearing loss.
Congenital CMV infection is diagnosed by detection of CMV DNA in the urine, saliva (preferred specimens), or blood, within two to three weeks after birth. Infection cannot be diagnosed using tests that detect antibodies to CMV. Congenital CMV infection cannot be diagnosed using samples collected more than two to three weeks after birth because testing after this time cannot distinguish between congenital infection and an infection acquired during or after delivery.
For diagnosis of acquired CMV infection see Interpretation of Laboratory Tests.
For infants with signs of congenital CMV disease at birth, antiviral medications, such as ganciclovir or valganciclovir, may improve hearing and developmental outcomes. Ganciclovir can have serious side effects and has only been studied in infants with symptomatic congenital CMV disease. There is limited information on the effectiveness of ganciclovir or valganciclovir to treat infants with hearing loss alone.
Any infant diagnosed with congenital CMV infection should have regular hearing and vision tests. Most infants with congenital CMV grow up healthy. However, if the child has delayed onset of hearing or vision problems, early detection may improve outcomes. To learn more, see this CDC website about hearing loss in children.
- Fact Sheet: Diagnose, treat, and monitor children with congenital cytomegalovirus (CMV) to help improve their health outcomes. [2 pages]
- Facts about Intellectual Disability (English/Spanish) [2 pages]
- Congenital CMV and Hearing Loss: What’s the Risk?
D. Tatiana Lanzieri, a medical epidemiologist at CDC, discusses findings from a study on hearing loss among children with congenital cytomegalovirus (CMV) infection, as part of the CDC Expert Cmmentary series on Medscape.
- Page last reviewed: June 6, 2018
- Page last updated: June 6, 2018
- Content source: